Breaking News Instant updates and real-time market news.

BBIO

BridgeBio

$29.12 /

-0.59 (-1.99%)

07:10
06/11/20
06/11
07:10
06/11/20
07:10

BridgeBio's ML Bio Solutions doses first subject in Phase 1 trial of BBP-418

BridgeBio Pharma affiliate ML Bio Solutions announced that the first subject has been dosed in the Phase 1 clinical trial of BBP-418, an orally-administered small molecule therapy being evaluated for the treatment of limb girdle muscular dystrophy type 2i. The Phase 1 clinical trial is designed to assess safety, tolerability, pharmacokinetics and food effect of BBP-418 in healthy volunteers. In collaboration with the GRASP-LGMD consortium based at Virginia Commonwealth University, which is led by Nicholas Johnson, M.D., M.S.C.I., ML Bio Solutions is also enrolling a LGMD2i lead-in study across multiple centers in the U.S. and Europe. ML Bio Solutions also announced that the U.S. Food and Drug Administration approved its Investigational New Drug application for BBP-418 in March 2020. LGMD2i is an inherited muscular dystrophy that is associated with two mutant copies of a gene called fukutin-related protein (FKRP). The FKRP enzyme enables the proper functioning of a fully glycosylated alpha-dystroglycan protein on muscle cells. While fully glycosylated alpha-DG anchors the inside and the outside of cells to act as a "shock-absorber," hypo-glycosylated alpha-DG - such as occurs in LGMD2i and fukutinopathies - leads to muscle cells that cannot withstand the stress of normal cellular activities. ML Bio Solutions' oral therapy BBP-418 is designed to enhance the function of enzymes like FKRP in order to restore glycosylation levels of alpha-DG protein and thereby recover its shock absorber functionality. The hope is that BBP-418 is ultimately able to change the prognosis of patients with LGMD2i - who experience progressive loss of skeletal, respiratory and cardiac muscle strength that leads to loss of walking, need for ventilatory support and even death from heart failure - and who today have only palliative treatment options. BBP-418 has previously been granted Orphan Drug Designation for LGMD2i by the FDA. At this pivotal juncture, ML Bio Solutions has appointed a chief medical officer, Douglas Sproule, M.D. M.Sc., to lead clinical development as well as regulatory strategy and affairs for BBP-418. Dr. Sproule is a trained pediatric neuro-muscular specialist who worked most recently as vice president, clinical development and medical affairs and spinal muscular atrophy therapeutic area head at AveXis.

BBIO BridgeBio
$29.12 /

-0.59 (-1.99%)

06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
05/19/20 BTIG
BridgeBio initiated with a Buy at BTIG
05/11/20 Piper Sandler
Piper Sandler says BridgeBio's Infigratinib 'attractive candidate' for ACH

TODAY'S FREE FLY STORIES

Hot Stocks
INmune Bio announces interim phase 1B data on XPro1595 in Alzheimer's » 16:18
07/13/20
07/13
16:18
07/13/20
16:18
INMB

INmune Bio

$8.74 /

+1.72 (+24.50%)

INmune Bio reported…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

03/12/20 H.C. Wainwright
INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
03/11/20 Roth Capital
INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital
12/18/19 Roth Capital
INmune Bio initiated with a Buy at Roth Capital
08/21/19
Fly Intel: Top five analyst initiations
INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

Conference/Events
Oppenheimer healthcare analysts to hold an analyst/industry conference call » 16:18
07/13/20
07/13
16:18
07/13/20
16:18

Healthcare Analysts…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Hot Stocks
Invesco reports AUM of $1.145T as of June 30, 2020 » 16:18
07/13/20
07/13
16:18
07/13/20
16:18
IVZ

Invesco

$10.62 /

+0.1 (+0.95%)

Invesco reported…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
IVZ Invesco
$10.62 /

+0.1 (+0.95%)

IVZ Invesco
$10.62 /

+0.1 (+0.95%)

04/24/20 Citi
Invesco price target lowered to $4.50 from $5.50 at Citi
04/23/20 Keefe Bruyette
Invesco downgraded to Market Perform from Outperform at Keefe Bruyette
04/15/20 Citi
Invesco downgraded to Sell from Neutral at Citi
03/16/20 JPMorgan
Invesco price target lowered to $8 from $20 at JPMorgan
IVZ Invesco
$10.62 /

+0.1 (+0.95%)

IVZ Invesco
$10.62 /

+0.1 (+0.95%)

IVZ Invesco
$10.62 /

+0.1 (+0.95%)

IVZ Invesco
$10.62 /

+0.1 (+0.95%)

Hot Stocks
Town Sports receives Nasdaq notice over listing standard non-compliance » 16:17
07/13/20
07/13
16:17
07/13/20
16:17
CLUB

Town Sports

$0.45 /

-0.0286 (-5.96%)

Town Sports International…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CLUB Town Sports
$0.45 /

-0.0286 (-5.96%)

CLUB Town Sports
$0.45 /

-0.0286 (-5.96%)

Technical Analysis
NASDAQ market internals summary » 16:17
07/13/20
07/13
16:17
07/13/20
16:17
$NSD

NASDAQ Market Internals

$0.00 /

+ (+0.00%)

Volume was above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
$0.00 /

+ (+0.00%)

Hot Stocks
Edwards Lifesciences, Abbott settle global transcatheter patent litigation » 16:16
07/13/20
07/13
16:16
07/13/20
16:16
ABT

Abbott

$93.13 /

+0.09 (+0.10%)

, EW

Edwards Lifesciences

$67.18 /

-0.67 (-0.99%)

Abbott (ABT) announced it…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABT Abbott
$93.13 /

+0.09 (+0.10%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

ABT Abbott
$93.13 /

+0.09 (+0.10%)

07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
06/15/20 Piper Sandler
Abbott approval narrows competitive gap to DexCom, says Piper Sandler
06/11/20 UBS
Abbott's COVID-19 testing positive contributor, says UBS
06/09/20 Barrington
Surmodics price target raised to $62 from $56 at Barrington
EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

06/05/20 Piper Sandler
Post points to Edwards resuming recruiting for CLASP trial, says Piper Sandler
04/28/20 Wells Fargo
Edwards Lifesciences downgraded on sales growth gap at Wells Fargo
04/28/20 Wells Fargo
Edwards Lifesciences downgraded to Equal Weight from Overweight at Wells Fargo
04/27/20 Barclays
Edwards Lifesciences price target lowered to $155 from $165 at Barclays
ABT Abbott
$93.13 /

+0.09 (+0.10%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

ABT Abbott
$93.13 /

+0.09 (+0.10%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

ABT Abbott
$93.13 /

+0.09 (+0.10%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

ABT Abbott
$93.13 /

+0.09 (+0.10%)

Initiation
Cavco Industries initiated with a Neutral at Wedbush » 16:16
07/13/20
07/13
16:16
07/13/20
16:16
CVCO

Cavco Industries

$180.93 /

-4.32 (-2.33%)

Wedbush analyst Jay…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CVCO Cavco Industries
$180.93 /

-4.32 (-2.33%)

CVCO Cavco Industries
$180.93 /

-4.32 (-2.33%)

05/28/20 Craig-Hallum
Cavco Industries price target raised to $204 from $142 at Craig-Hallum
04/02/20 Craig-Hallum
Cavco Industries price target lowered to $142 from $215 at Craig-Hallum
02/03/20 Craig-Hallum
Cavco Industries price target raised to $215 from $192 at Craig-Hallum
07/31/19 Craig-Hallum
Cavco Industries price target raised to $173 from $153 at Craig-Hallum
CVCO Cavco Industries
$180.93 /

-4.32 (-2.33%)

Technical Analysis
NYSE market internals summary » 16:16
07/13/20
07/13
16:16
07/13/20
16:16
$NYE

NYSE Market Internals

$0.00 /

+ (+0.00%)

Volume was above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$NYE NYSE Market Internals
$0.00 /

+ (+0.00%)

Hot Stocks
Jefferies Financial Group names Matthew Larson CFO » 16:16
07/13/20
07/13
16:16
07/13/20
16:16
JEF

Jefferies Financial Group

$16.28 /

+0.255 (+1.59%)

Jefferies Group LLC…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
JEF Jefferies Financial Group
$16.28 /

+0.255 (+1.59%)

JEF Jefferies Financial Group
$16.28 /

+0.255 (+1.59%)

11/01/19
Rice University-Jones Graduate School of Business to hold a summit
10/15/19 Deutsche Bank
Deutsche places 'Catalyst Call' buy on Spectrum Brands after selloff
JEF Jefferies Financial Group
$16.28 /

+0.255 (+1.59%)

JEF Jefferies Financial Group
$16.28 /

+0.255 (+1.59%)

Syndicate
Osmotica Pharmaceuticals files to sell 5M ordinary shares » 16:15
07/13/20
07/13
16:15
07/13/20
16:15
OSMT

Osmotica Pharmaceuticals

$7.71 /

-1.06 (-12.09%)

Credit Suisse Securities…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

07/10/20 SunTrust
Osmotica Pharmaceuticals price target raised to $11 from $8 at SunTrust
07/09/20 RBC Capital
Osmotica price target raised to $12 from $10 at RBC Capital
03/23/20 Wells Fargo
Wells Fargo downgrades Osmotica to Equal Weight, halves price target to $4
03/23/20 Wells Fargo
Osmotica Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

  • 09
    Jan
OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

Initiation
Relmada Therapeutics initiated with an Outperform at Oppenheimer » 16:13
07/13/20
07/13
16:13
07/13/20
16:13
RLMD

Relmada Therapeutics

$40.65 /

-1.43 (-3.40%)

, SAGE

Sage Therapeutics

$41.13 /

-1.76 (-4.10%)

, ACAD

Acadia

$52.48 /

-2.99 (-5.39%)

, AXSM

Axsome Therapeutics

$76.78 /

-6.24 (-7.52%)

, JNJ

Johnson & Johnson

$145.18 /

+2.73 (+1.92%)

Oppenheimer analyst Jay…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RLMD Relmada Therapeutics
$40.65 /

-1.43 (-3.40%)

SAGE Sage Therapeutics
$41.13 /

-1.76 (-4.10%)

ACAD Acadia
$52.48 /

-2.99 (-5.39%)

AXSM Axsome Therapeutics
$76.78 /

-6.24 (-7.52%)

JNJ Johnson & Johnson
$145.18 /

+2.73 (+1.92%)

RLMD Relmada Therapeutics
$40.65 /

-1.43 (-3.40%)

05/27/20 Goldman Sachs
Goldman says Relmada clearance for Phase 3 supports REL-1017 safety, efficacy
05/04/20 SunTrust
Relmada Therapeutics initiated with a Buy at SunTrust
05/04/20
Fly Intel: Top five analyst initiations
04/21/20 Goldman Sachs
Relmada Therapeutics initiated with a Buy at Goldman Sachs
SAGE Sage Therapeutics
$41.13 /

-1.76 (-4.10%)

05/26/20 RBC Capital
Sage Therapeutics price target raised to $75 from $72 at RBC Capital
05/08/20 Wedbush
Sage Therapeutics downgraded at Wedbush on lack of catalysts
05/08/20 Wedbush
Sage Therapeutics downgraded to Neutral from Outperform at Wedbush
05/08/20 Mizuho
Sage Therapeutics price target raised to $44 from $36 at Mizuho
ACAD Acadia
$52.48 /

-2.99 (-5.39%)

07/09/20 RBC Capital
Acadia price target raised to $61 from $58 at RBC Capital
07/07/20
Fly Intel: Top five analyst upgrades
07/06/20 Stifel
Acadia upgraded to Buy from Hold at Stifel
06/24/20 Citi
Acadia risk/reward skewed to upside into depression data, says Citi
AXSM Axsome Therapeutics
$76.78 /

-6.24 (-7.52%)

04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 SunTrust
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
04/28/20 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $200 at H.C. Wainwright
JNJ Johnson & Johnson
$145.18 /

+2.73 (+1.92%)

08:42 Today H.C. Wainwright
Pacira price target raised to $68 from $63 at H.C. Wainwright
07/10/20 Jefferies
Pacira price target raised to $69 from $53 at Jefferies
07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
SAGE Sage Therapeutics
$41.13 /

-1.76 (-4.10%)

ACAD Acadia
$52.48 /

-2.99 (-5.39%)

AXSM Axsome Therapeutics
$76.78 /

-6.24 (-7.52%)

JNJ Johnson & Johnson
$145.18 /

+2.73 (+1.92%)

  • 19
    Dec
  • 04
    Dec
  • 18
    Sep
JNJ Johnson & Johnson
$145.18 /

+2.73 (+1.92%)

ACAD Acadia
$52.48 /

-2.99 (-5.39%)

AXSM Axsome Therapeutics
$76.78 /

-6.24 (-7.52%)

JNJ Johnson & Johnson
$145.18 /

+2.73 (+1.92%)

AXSM Axsome Therapeutics
$76.78 /

-6.24 (-7.52%)

JNJ Johnson & Johnson
$145.18 /

+2.73 (+1.92%)

Syndicate
Postal Realty Trust files to sell 3.5M shares of common stock » 16:10
07/13/20
07/13
16:10
07/13/20
16:10
PSTL

Postal Realty Trust

$15.70 /

+1.05 (+7.17%)

Jefferies and Stifel are…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PSTL Postal Realty Trust
$15.70 /

+1.05 (+7.17%)

PSTL Postal Realty Trust
$15.70 /

+1.05 (+7.17%)

06/04/20 BTIG
Postal Realty Trust initiated with a Buy at BTIG
12/18/19 Compass Point
Postal Realty Trust initiated with a Buy at Compass Point
12/18/19 Compass Point
Postal Realty Trust initiated with a Buy at Compass Point
12/18/19 Compass Point
Postal Realty Trust initiated with a Buy at Compass Point
PSTL Postal Realty Trust
$15.70 /

+1.05 (+7.17%)

Initiation
Frequency Therapeutics initiated with an Outperform at Oppenheimer » 16:10
07/13/20
07/13
16:10
07/13/20
16:10
FREQ

Frequency Therapeutics

$20.60 /

-2.23 (-9.77%)

Oppenheimer analyst Jay…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FREQ Frequency Therapeutics
$20.60 /

-2.23 (-9.77%)

FREQ Frequency Therapeutics
$20.60 /

-2.23 (-9.77%)

05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
FREQ Frequency Therapeutics
$20.60 /

-2.23 (-9.77%)

  • 03
    Oct
FREQ Frequency Therapeutics
$20.60 /

-2.23 (-9.77%)

Hot Stocks
Seacoast Banking hires Austen Carroll as chief lending officer » 16:09
07/13/20
07/13
16:09
07/13/20
16:09
SBCF

Seacoast Banking

$18.48 /

+0.29 (+1.59%)

Seacoast Banking…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SBCF Seacoast Banking
$18.48 /

+0.29 (+1.59%)

SBCF Seacoast Banking
$18.48 /

+0.29 (+1.59%)

07/02/20 B. Riley FBR
Seacoast Banking upgraded to Buy with $25 target at B. Riley FBR
07/02/20 B. Riley FBR
Seacoast Banking upgraded to Buy from Neutral at B. Riley FBR
06/04/20 B. Riley FBR
Seacoast Banking price target raised to $25 from $21 at B. Riley FBR
01/09/20 B. Riley FBR
Seacoast Banking upgraded to Buy from Neutral at B. Riley FBR
SBCF Seacoast Banking
$18.48 /

+0.29 (+1.59%)

Hot Stocks
Grinrod Shipping re-delivers Doric Breeze to owners » 16:09
07/13/20
07/13
16:09
07/13/20
16:09
GRIN

Grinrod Shipping

$2.70 /

-0.25 (-8.47%)

Grindrod Shipping…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GRIN Grinrod Shipping
$2.70 /

-0.25 (-8.47%)

GRIN Grinrod Shipping
$2.70 /

-0.25 (-8.47%)

01/09/20 Noble Capital
Grinrod Shipping initiated with an Outperform at Noble Capital
Hot Stocks
Merus, Caris Life Sciences announce collaboration to detect NRG1 fusions » 16:07
07/13/20
07/13
16:07
07/13/20
16:07
MRUS

Merus

$13.64 /

-0.77 (-5.34%)

Merus and Caris Life…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRUS Merus
$13.64 /

-0.77 (-5.34%)

MRUS Merus
$13.64 /

-0.77 (-5.34%)

06/26/20 H.C. Wainwright
Merus initiated with a Buy at H.C. Wainwright
05/27/20
Fly Intel: Top five analyst downgrades
05/27/20 RBC Capital
Merus downgraded to Sector Perform from Outperform at RBC Capital
05/27/20 RBC Capital
Merus downgraded to Sector Perform from Outperform at RBC Capital
  • 05
    Nov
Upgrade
Nikon upgraded to Equal Weight from Underweight at Morgan Stanley » 16:06
07/13/20
07/13
16:06
07/13/20
16:06
NINOY

Nikon

$0.00 /

+ (+0.00%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NINOY Nikon
$0.00 /

+ (+0.00%)

12/19/19 Nomura Instinet
Nikon downgraded to Neutral from Buy at Nomura Instinet
Hot Stocks
Ramaco Resources announces partial closure at Berwind mine complex » 16:06
07/13/20
07/13
16:06
07/13/20
16:06
METC

Ramaco Resources

$2.47 /

+0.11 (+4.66%)

Ramaco Resources…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
METC Ramaco Resources
$2.47 /

+0.11 (+4.66%)

METC Ramaco Resources
$2.47 /

+0.11 (+4.66%)

02/25/20
Fly Intel: Top five analyst initiations
02/25/20 Benchmark
Benchmark starts Ramaco Resources at Buy, sees doubling production as possible
02/25/20 Benchmark
Ramaco Resources initiated with a Buy at Benchmark
08/06/19 Jefferies
Ramaco Resources downgraded to Hold from Buy at Jefferies
METC Ramaco Resources
$2.47 /

+0.11 (+4.66%)

Hot Stocks
Orion Group announces contract award of roughly $15M » 16:05
07/13/20
07/13
16:05
07/13/20
16:05
ORN

Orion Group

$2.78 /

+0.06 (+2.21%)

Orion Group Holdings…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ORN Orion Group
$2.78 /

+0.06 (+2.21%)

ORN Orion Group
$2.78 /

+0.06 (+2.21%)

ORN Orion Group
$2.78 /

+0.06 (+2.21%)

Hot Stocks
Immunomedics expands collaboration with Roche to evaluate Trodelvy and Tecentriq » 16:04
07/13/20
07/13
16:04
07/13/20
16:04
IMMU

Immunomedics

$40.12 /

-1.16 (-2.81%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Immunomedics (IMMU)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IMMU Immunomedics
$40.12 /

-1.16 (-2.81%)

RHHBY Roche
$0.00 /

+ (+0.00%)

IMMU Immunomedics
$40.12 /

-1.16 (-2.81%)

07/07/20 Guggenheim
Immunomedics price target raised to $52 after 'best case' data at Guggenheim
07/07/20 H.C. Wainwright
Immunomedics price target raised to $56 from $54 at H.C. Wainwright
07/06/20 Piper Sandler
Immunomedics price target raised to $55 from $40 at Piper Sandler
07/06/20 Wells Fargo
Immunomedics price target raised to $55 from $41 at Wells Fargo
RHHBY Roche
$0.00 /

+ (+0.00%)

06:01 Today Bernstein
Roche initiated with an Outperform at Bernstein
07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
IMMU Immunomedics
$40.12 /

-1.16 (-2.81%)

RHHBY Roche
$0.00 /

+ (+0.00%)

  • 29
    Apr
  • 05
    Dec
IMMU Immunomedics
$40.12 /

-1.16 (-2.81%)

RHHBY Roche
$0.00 /

+ (+0.00%)

IMMU Immunomedics
$40.12 /

-1.16 (-2.81%)

RHHBY Roche
$0.00 /

+ (+0.00%)

IMMU Immunomedics
$40.12 /

-1.16 (-2.81%)

Syndicate
Altimmune files to sell common stock and pre-funded warrants » 16:03
07/13/20
07/13
16:03
07/13/20
16:03
ALT

Altimmune

$26.37 /

+4.05 (+18.15%)

Jefferies, Evercore ISI…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ALT Altimmune
$26.37 /

+4.05 (+18.15%)

ALT Altimmune
$26.37 /

+4.05 (+18.15%)

06/01/20 Roth Capital
Altimmune surprises with differentiated T-COVID study, says Roth Capital
05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
ALT Altimmune
$26.37 /

+4.05 (+18.15%)

ALT Altimmune
$26.37 /

+4.05 (+18.15%)

ALT Altimmune
$26.37 /

+4.05 (+18.15%)

Hot Stocks
Wins Finance granted continued listing on Nasdaq » 16:03
07/13/20
07/13
16:03
07/13/20
16:03
WINS

Wins Finance

$27.00 /

-1.83 (-6.35%)

Wins Finance Holdings…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WINS Wins Finance
$27.00 /

-1.83 (-6.35%)

Syndicate
Altimmune files to sell common stock, no amount given » 16:02
07/13/20
07/13
16:02
07/13/20
16:02
ALT

Altimmune

$26.37 /

+4.05 (+18.15%)

Jefferies, Evercore ISI…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ALT Altimmune
$26.37 /

+4.05 (+18.15%)

ALT Altimmune
$26.37 /

+4.05 (+18.15%)

06/01/20 Roth Capital
Altimmune surprises with differentiated T-COVID study, says Roth Capital
05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
ALT Altimmune
$26.37 /

+4.05 (+18.15%)

ALT Altimmune
$26.37 /

+4.05 (+18.15%)

ALT Altimmune
$26.37 /

+4.05 (+18.15%)

Hot Stocks
Patriot National names Robert Russell President and CEO » 16:02
07/13/20
07/13
16:02
07/13/20
16:02
PNBK

Patriot National

$6.01 /

-0.16 (-2.59%)

Patriot National Bancorp…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Periodicals
Apple sees 2020 return to offices unlikely, pushes remote work, Bloomberg says » 15:56
07/13/20
07/13
15:56
07/13/20
15:56
AAPL

Apple

$385.34 /

+1.78 (+0.46%)

Apple is readjusting…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AAPL Apple
$385.34 /

+1.78 (+0.46%)

AAPL Apple
$385.34 /

+1.78 (+0.46%)

07:42 Today Wedbush
Wedbush boosts Apple target to $450 ahead of 'massive' iPhone cycle
07:39 Today KeyBanc
Data indicates 'strong recovery' in Apple iPhone sales, says KeyBanc
06:40 Today Morgan Stanley
Apple price target raised to $419 from $340 at Morgan Stanley
07/09/20 Nomura Instinet
Nomura says Apple iPhone shipments in China pressured by 5G models in June
AAPL Apple
$385.34 /

+1.78 (+0.46%)

AAPL Apple
$385.34 /

+1.78 (+0.46%)

AAPL Apple
$385.34 /

+1.78 (+0.46%)

AAPL Apple
$385.34 /

+1.78 (+0.46%)

AAPL Apple
$385.34 /

+1.78 (+0.46%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.